Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4HE | ISIN: US29415J1060 | Ticker-Symbol: 5HJ
Tradegate
25.04.24
19:33 Uhr
4,880 Euro
-0,020
-0,41 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ENVVENO MEDICAL CORPORATION Chart 1 Jahr
5-Tage-Chart
ENVVENO MEDICAL CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
4,8204,94011:45

Aktuelle News zur ENVVENO MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MienVVeno Medical Corporation: Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium166Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement = 3 Points) including:9.29 Points for...
► Artikel lesen
MienVVeno Medical Corp - 8-K, Current Report2
16.04.enVVeno Medical Corporation: New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024293IRVINE, CA / ACCESSWIRE / April 16, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
09.04.enVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer315Appointment bolsters Company's transition from being a clinical stage to a commercial entity planning for the monetization of the VenoValve®PMA application seeking FDA approval for the VenoValve on...
► Artikel lesen
16.03.Envveno Medical CTO sells $51,837 in company stock1
15.03.enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity341Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, March 21st at 12:00 PM ETIRVINE, CA / ACCESSWIRE / March 15, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO)...
► Artikel lesen
06.03.BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers4
06.03.enVVeno Medical Corporation: Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting25797% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as Measured by the Revised Venous Clinical Severity Score (rVCSS))74% of the Study Patients Showing Clinical Meaningful Benefit...
► Artikel lesen
06.03.enVVeno Medical Corp - 8-K, Current Report2
01.03.enVVeno Medical Corp reports results for the quarter ended in December - Earnings Summary1
01.03.enVVeno Medical reports FY results1
29.02.Recap: enVVeno Medical Q4 Earnings1
29.02.enVVeno Medical Corp - 10-K, Annual Report-
29.02.enVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update400$46.4 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025Topline efficacy data for VenoValve® U.S. pivotal...
► Artikel lesen
27.02.enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview1
20.02.enVVeno Medical Corporation: Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024296IRVINE, CA / ACCESSWIRE / February 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...
► Artikel lesen
13.02.enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview1
02.02.enVVeno Medical Corp expected to post a loss of 46 cents a share - Earnings Preview1
14.12.23enVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium409- Interviews with patients from the VenoValve® pivotal study- Materials now available on the Company's websiteIRVINE, CA / ACCESSWIRE / December 14, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO)...
► Artikel lesen
07.12.23enVVeno Medical Corp - 8-K, Current Report1
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1